Thalassemia Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Thalassemia Treatment Market Analysis
The thalassemia treatment market studied was projected to grow with a CAGR of nearly 7.6% over the forecast period. The major factors attributing to the growth of the market are increasing prevalence of thalassemia and also growing awareness to treat thalassemia. According to National Center on Birth Defects and Developmental Disabilities, thalassemia, affects at least 1,000 people in the United States. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companies boosting the market growth. Chelation therapy and blood transfusion are the conventional treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion method for purifying blood, raise the possibility of curing thalassemia in patients. However the high cost of the treatment is major drawback for the market growth.
Thalassemia Treatment Market Trends
This section covers the major market trends shaping the Thalassemia Treatment Market according to our research experts:
Chelation Therapy segment is expected to be the Fastest Growing Segment
- Iron overload is the main cause of sickness for thalassemia patients. Even non- transfused patients develop iron overload secondary to boosted intestinal absorption of dietary iron. Iron overload is a leading cause of mortality and organ injury. The only treatment options for removing excess iron are phlebotomy and chelation. While phlebotomy is a very effective way of removing iron, it is not appropriate for patients with thalassemia except after bone marrow transplantation.
- The segment is projected to expand at an exponential growth rate during the forecast period. The major factors driving the growth of the segment are increasing incidence of thalassemia patients and increasing research and development investments.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall thalassemia treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of thalassemia patients in the region and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth. The United States has the main share due to the rising awareness about the condition and increasing number of populations with thalassemia carrier gene, and growth in birth rates due to variation of genes among the population.
Thalassemia Treatment Industry Overview
The thalassemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Bluebird Bio, IONIS Pharmaceuticals, Novartis AG, Bellicum Pharmaceuticals, ApoPharma Inc, SG Pharma Pvt. Lmt. Acceleron Pharma, Inc., and Kiadis Pharma, Lonza Group Ltd.,
Thalassemia Treatment Market Leaders
-
Bluebird Bio
-
Novartis AG
-
ApoPharma Inc
-
Bellicum Pharmaceuticals
-
Pfizer, Inc.
*Disclaimer: Major Players sorted in no particular order
Thalassemia Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Thalassemia
- 4.2.2 Increasing Awareness of Thalassemia Treatment
-
4.3 Market Restraints
- 4.3.1 High Cost of Treatment
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Treatment Type
- 5.1.1 Blood Transfusions
- 5.1.2 Iron Chelation Therapy
- 5.1.3 Folic Acid Supplements
- 5.1.4 Others
-
5.2 By Disease Type
- 5.2.1 Alpha Thalassemia
- 5.2.2 Beta Thalassemia
-
5.3 By End-User
- 5.3.1 Hospitals
- 5.3.2 Research Institutes
- 5.3.3 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Bluebird Bio
- 6.1.2 IONIS Pharmaceuticals
- 6.1.3 Novartis AG
- 6.1.4 Bellicum Pharmaceuticals
- 6.1.5 ApoPharma Inc
- 6.1.6 Pfizer, Inc.
- 6.1.7 Acceleron Pharma, Inc.
- 6.1.8 Kiadis Pharma
- 6.1.9 SG Phrma Pvt. Lmt.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityThalassemia Treatment Industry Segmentation
As per the scope of the report thalassemia is a blood disorder passed down through families in which the body makes an abnormal form or insufficient amount of hemoglobin. This report is segmented by Treatment Type, by Disease Type, by End-User, and by Geography.
| By Treatment Type | Blood Transfusions | |
| Iron Chelation Therapy | ||
| Folic Acid Supplements | ||
| Others | ||
| By Disease Type | Alpha Thalassemia | |
| Beta Thalassemia | ||
| By End-User | Hospitals | |
| Research Institutes | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Thalassemia Treatment Market Research FAQs
What is the current Thalassemia Treatment Market size?
The Thalassemia Treatment Market is projected to register a CAGR of 7.60% during the forecast period (2024-2029)
Who are the key players in Thalassemia Treatment Market?
Bluebird Bio, Novartis AG, ApoPharma Inc, Bellicum Pharmaceuticals and Pfizer, Inc. are the major companies operating in the Thalassemia Treatment Market.
Which is the fastest growing region in Thalassemia Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Thalassemia Treatment Market?
In 2024, the North America accounts for the largest market share in Thalassemia Treatment Market.
What years does this Thalassemia Treatment Market cover?
The report covers the Thalassemia Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Thalassemia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Thalassemia Treatment Industry Report
Statistics for the 2024 Thalassemia Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Thalassemia Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
